PON1 and hepatocellular carcinoma: The upregulation of PON1 by atorvastatin could be explained by means of the in vitro results from human hepatoma HepG2 cells and human embryonic kidney 293 cells, which revealed that atorvastatin, as simvastatin and pitavastatin, increase PON1 promoter activity through an inhibition of mevalonic acid-derived famesyl pyrophosphate (FFP) pathway [79].